InSysBio announces its participation in ChinaBio Partnering Forum 2026 which is to be held from April 28–29, 2026 in Shanghai, China. InSysBio team is going to present its QSP modeling services & software to optimize drug development at Booth #B302 and a poster at the Antibody & ADC Summit:
Tuesday, April 28:
Check out our poster and Booth #B302!
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | November 2019 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
| ||||
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
|
18
1.
18 Nov 2019 19:58
Course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics
This year InSysBio CEO Dr Oleg Demin with expert modelers Tatiana Karelina and Evgeny Metelkin and modelers Dmitry Shchelokov, Svetlana Rubina and Veronika Musatova are giving the course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University.
|
19
|
20
|
21
|
22
|
23
|
24
|
|
25
1.
25 Nov 2019 18:47
PK/RO simulator for anti-PD-1 mAbs
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced the launch of application ‘PK/RO simulator for anti-PD-1 mAbs’. The application is based on the model allowing to predict pharmacokinetics and target binding in human for therapeutic antibodies against PD-1 receptor.
|
26
|
27
|
28
|
29
|
30
| |
Thank you for your message! We will get back to you shortly.
